Macrophage activation and inflammatory priming by anti-MAA antibodies in rheumatoid arthritis

Clin Immunol. 2024 Aug:265:110303. doi: 10.1016/j.clim.2024.110303. Epub 2024 Jul 3.

Abstract

We studied the effects of rheumatoid arthritis (RA) autoantibodies that target malondialdehyde-acetaldehyde protein adducts (anti-MAA) on inflammation and macrophage functions. We detected a profound reprogramming of gene expressions and the production of chemokines, such as CCL22 and CCL24, in anti-MAA exposed macrophages. Moreover, anti-MAA pretreatment promoted a more inflammatory cytokine profile upon TLR activation. Although anti-MAA are typically multi-reactive, we observed a prominent clonal diversity in inducing macrophage activation. Anti-MAA antibodies were not arthritogenic in mice, but altered a set of cytokine and growth factor encoding genes in the joints. In individuals at risk of RA anti-MAA IgG levels correlated with circulating inflammatory mediators prior to and at arthritis onset. Certain IgG anti-MAA clones may thus contribute to an inflammatory priming of the joint prior to the onset of systemic inflammation via inducing FcγR-mediated macrophage pre-activation and setting the stage for augmented responses to subsequent inflammatory stimuli.

Keywords: Anti-MAA; Autoantibody; Inflammation; Macrophage; Rheumatoid arthritis; Risk RA phase.

MeSH terms

  • Acetaldehyde* / immunology
  • Animals
  • Arthritis, Rheumatoid* / immunology
  • Autoantibodies* / immunology
  • Cytokines / immunology
  • Cytokines / metabolism
  • Female
  • Humans
  • Immunoglobulin G / immunology
  • Inflammation / immunology
  • Macrophage Activation* / immunology
  • Macrophages* / immunology
  • Male
  • Malondialdehyde* / immunology
  • Mice
  • Middle Aged

Substances

  • Autoantibodies
  • Acetaldehyde
  • Malondialdehyde
  • Cytokines
  • Immunoglobulin G